BeOne Medicines’ BEQALZI™ Receives U.S. FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines has announced that the U.S. Food and Drug Administration has granted accelerated approval to BEQALZI for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two lines of systemic therapy, including treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. The approval marks a significant milestone for the company and introduces a new targeted treatment option for patients facing limited therapeutic choices after disease progression.
BEQALZI, also known by its generic name sonrotoclax, is a next-generation BCL2 inhibitor developed to improve upon earlier therapies within the same drug class. According to BeOne Medicines, the therapy was specifically designed to deliver stronger and more selective BCL2 inhibition while offering a pharmacologic profile that could potentially improve efficacy, tolerability, and treatment convenience compared with existing options.
The approval further strengthens BeOne’s expanding hematology and oncology portfolio and reflects increasing momentum in the development of targeted therapies for B-cell malignancies. Mantle cell lymphoma remains one of the more difficult forms of non-Hodgkin lymphoma to treat, particularly in patients whose disease has relapsed following prior therapies.
Michael Wang, Global Principal Investigator for the study supporting the approval and professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, stated that the U.S. approval of sonrotoclax confirms the drug’s role as a potentially foundational therapy for patients with mantle cell lymphoma in the post-BTK inhibitor setting.
According to Wang, treatment options for patients who relapse after BTK inhibitor therapy remain limited, and outcomes are often poor. He explained that the data generated so far suggest sonrotoclax can provide meaningful disease control while maintaining a tolerable safety profile, giving physicians a potentially important new option for sequencing therapy in this aggressive disease.
The FDA’s accelerated approval decision was supported by efficacy and safety results from the Phase 1/2 BGB-11417-201 clinical study, registered under ClinicalTrials.gov identifier NCT05471843. Findings from the trial were presented during the American Society of Hematology Annual Meeting and included independently reviewed efficacy assessments.
Clinical data from the study demonstrated an overall response rate (ORR) of 52%, with a 95% confidence interval ranging from 42% to 62%. The study also reported a complete response rate of 16%, indicating that a subset of patients achieved complete remission following treatment with sonrotoclax.
The median time to response was reported at 1.9 months, suggesting that many patients experienced therapeutic benefit relatively quickly after starting treatment. In addition, the median duration of response reached 15.8 months at a median response follow-up period of 11.9 months, although investigators noted that the data had not yet fully matured.
Researchers also reported that sonrotoclax monotherapy was generally well tolerated, an important consideration for heavily pretreated patients with relapsed or refractory disease who may have already experienced substantial treatment-related toxicity from previous therapies.
Under the FDA’s accelerated approval pathway, continued approval for BEQALZI in mantle cell lymphoma will depend on verification of clinical benefit through ongoing confirmatory studies. BeOne Medicines confirmed that the confirmatory Phase 3 CELESTIAL-RRMCL trial, identified as NCT06742996, is currently underway.
The FDA has previously granted several regulatory designations to sonrotoclax in recognition of its potential therapeutic importance. These include Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for mantle cell lymphoma. Such designations are intended to support the development and review of therapies targeting serious diseases with unmet medical needs.
Amit Agarwal, Chief Medical Officer for Hematology at BeOne Medicines, said the approval represents an important advancement in the company’s broader effort to improve BCL2-targeted therapies for patients with B-cell malignancies.
According to Agarwal, BeOne’s strategy is focused on developing foundational medicines capable of raising the standard of care across hematologic cancers. He described the approval of BEQALZI as an important step forward for patients living with mantle cell lymphoma and emphasized the company’s commitment to continuing innovation within the field of targeted oncology therapeutics.
Mantle cell lymphoma is a relatively rare but aggressive subtype of non-Hodgkin lymphoma characterized by malignant transformation of B lymphocytes. In the United States, approximately 3,300 new cases are diagnosed annually. While many patients initially respond to frontline therapy, relapse remains common, and disease progression following BTK inhibitor therapy is often associated with poor prognosis and limited treatment options.
BTK inhibitors have significantly improved outcomes for many patients with mantle cell lymphoma over the past decade. However, resistance or relapse following BTK inhibitor therapy remains a major clinical challenge, creating demand for additional targeted treatment approaches capable of overcoming disease progression.
The approval of BEQALZI introduces a new BCL2-targeted mechanism into the treatment landscape for relapsed or refractory mantle cell lymphoma. BCL2 proteins play an important role in regulating cell survival, and overexpression of BCL2 is commonly associated with resistance to programmed cell death in certain blood cancers. By selectively inhibiting BCL2 activity, sonrotoclax is designed to help trigger apoptosis, or programmed cell death, in malignant B cells.
Patient advocacy organizations also welcomed the FDA approval as a meaningful development for the lymphoma community.
Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation, stated that each relapse experienced by patients with mantle cell lymphoma can create significant uncertainty regarding future treatment options and disease management.
Gutierrez noted that the FDA approval of sonrotoclax offers renewed hope for patients and families who may have exhausted previously available therapies. She emphasized that continued research and innovation remain essential for improving outcomes in mantle cell lymphoma and other hematologic malignancies.
Beyond the United States, sonrotoclax has already received regulatory approval in China for the treatment of relapsed or refractory mantle cell lymphoma. The therapy is also approved in China for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy, including a BTK inhibitor.
BeOne Medicines confirmed that regulatory submissions for sonrotoclax in relapsed or refractory mantle cell lymphoma are currently under review by the European Medicines Agency and additional global health authorities.
The company is also continuing to expand the broader development program for sonrotoclax across multiple hematologic malignancies. The FDA has granted Fast Track Designation for sonrotoclax in Waldenström macroglobulinemia, a rare form of non-Hodgkin lymphoma, as well as Orphan Drug Designation for several additional blood cancers and hematologic disorders.
These include multiple myeloma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and Waldenström macroglobulinemia. The additional regulatory designations highlight the growing interest in evaluating BCL2 inhibition across a broad range of malignancies where dysregulated apoptosis contributes to disease progression.
In addition to monotherapy development, sonrotoclax is being evaluated in combination regimens with other targeted therapies. One important area of investigation involves combination treatment with zanubrutinib for patients with chronic lymphocytic leukemia.
Updated data from these combination studies are expected to be presented during the American Society of Clinical Oncology Annual Meeting, where researchers and clinicians will continue evaluating the therapy’s potential role across multiple hematologic cancers.
The approval of BEQALZI reflects the broader transformation occurring within oncology as targeted therapies and precision medicine approaches continue reshaping treatment strategies for blood cancers. Advances in molecular biology and cancer genetics have enabled the development of therapies aimed at specific cellular pathways involved in tumor survival and resistance mechanisms.
For patients with relapsed or refractory mantle cell lymphoma, the introduction of another targeted therapeutic option may help expand treatment sequencing strategies and provide additional opportunities for disease control after prior therapies fail.
As BeOne Medicines continues advancing the development of sonrotoclax across multiple indications, the company is positioning the therapy as a potentially important component of future treatment approaches for B-cell malignancies and other hematologic cancers characterized by abnormal BCL2 signaling pathways.
About BEQALZI™ (sonrotoclax)
BEQALZI™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. Sonrotoclax has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,200 patients have been enrolled across the broad sonrotoclax global development program.
